2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5622 Beyond IPSS-m: A new prognostic scoring system for MDS-SF3B1 (IPSS-SF3B1)

Rami Komrokji, MD, Luca Lanino, MD2, Najla Al Ali, MS3, Rory Shallis, MD4, Zhuoer Xie, MD,MS5, Onyee Chan, MD6, Andrew T Kuykendall, MD7, Seongseok Yun, MD, PhD8, Samuel Benjamin Reynolds, MD9, Kendra L. Sweet, MD, MS10, Alison Walker, MD11, Joseph Jabbour12, Marta Ubezio, MD13, Matteo Zampini, PhD14, Valeria Santini, MD15, Jeffrey Lancet, MD16, Eric Padron, MD17, Matteo Giovanni Della Porta, MD18, David Sallman, MD19
1 Moffitt Cancer Center, Tampa, Florida, United States
2 IRCCS Humanitas Research Hospital, Milan, Italy
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 IRCCS Humanitas Research Hospital, Milan, Italy
14 IRCCS Humanitas Research Hospital, Milan, Italy
15 DMSC University of Florence, AOUC, Florence, Italy
16 Moffitt Cancer Center, Tampa, Florida, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 IRCCS Humanitas Research Hospital, Milan, Italy
19 Moffitt Cancer Center, Tampa, Florida, United States

Introduction

The 2022 WHO and ICC classifications recognize MDS-SF3B1 as a distinct subtype of myelodysplastic syndrome (MDS) with a generally favorable prognosis. However, most patients (pts) are categorized as lower risk by the Molecular International Prognostic Scoring System (IPSS-M), which limits the ability to identify pts with inferior outcomes and a higher risk of acute myeloid leukemia (AML) transformation in practice and on clinical trials. We developed a prognostic model specifically designed to identify variables associated with adverse outcomes in MDS-SF3B1 pts.

Methods

We identified pts with MDS-SF3B1 from our Moffitt Cancer Center database according to the 2022 WHO/ICC criteria: <5% bone marrow blasts, absence of complex karyotype, del(5q), chromosome 3 abnormalities, chromosome 7 abnormalities, and RUNX1 mutations. Univariable and multivariable Cox regression analyses were performed to assess clinical and genomic factors associated with outcomes. A prognostic model was developed using elastic-net regularized Cox regression with repeated stratified cross-validation. Model performance was assessed using the concordance index (C-index) and compared with IPSS-M. The model was validated in an external cohort.

Results

A total of 398 pts were included. Median age was 71years, median hemoglobin (hgb) 9.6 g/dL, and 21% were red blood cell-dependent (RBC-TD). The most common co-mutations were TET2 (34.3%), DNMT3A (19.2%), and ASXL1 (10.9%). By IPSS-M 20% (74), 63% (237), and 12% (45) were very low (VL), low (L), moderate low (ML) risk while only 5 % (19) were moderate high (MH), high (H) or very high risk (VH).  Only 23 pts progressed to AML and 159 died without AML transformation.

In univariable analysis, age, hgb, cytopenias, RBC-TD, blast%, SRSF2, DNMT3A, therapy-related MDS, albumin, Charlson Comorbidity Index, and creatinine were significantly associated with overall survival (OS). Other co-mutations, SF3B1 allele frequency, and hotspot loci were not.

In multivariable analysis, only age, hgb, RBC-TD, additional cytopenias, SRSF2, DNMT3A, and albumin remained independently associated with OS. A weighted point-based scoring system was developed using these variables. Pts were stratified into 3 risk groups: Low risk (0–8 points): n = 137, Intermediate risk (9–13 points): n = 156, and High risk (≥14 points): n = 105. The Median OS was 154.1 months, 90.8 months, and 51.8 months for the low, intermediate, and high-risk groups, respectively.

The model better risk stratified pts compared to IPSS-M. Among 74 pts labeled as VL risk IPSS-M, 31% (23) were upstaged to intermediate risk, and 3% (2) to higher risk. Among 237 pts labeled as L risk IPSS-M, 41% (97) were upstaged to intermediate risk and 28% (66) to higher risk. Among 45 pts labeled as ML risk IPSS-M, 44% (20) upstaged to intermediate risk and 40% (18) upstaged to higher risk. Only 19 pts by IPSS-M were MH/H/VH risk, only 1 pt was down staged to low risk.The model achieved a C-index of 0.72 for OS, outperforming IPSS-M (C-index 0.636). 

Leukemia-free survival (LFS) was 147.9 months, 83.0 months, and 44.6 months in the low-, intermediate-, and high-risk groups, respectively. The model demonstrated a C-index of 0.71 for LFS compared to 0.63 for IPSS-M.

The model was predictive of response to luspatercept, there was a strong trend for lower response rate in higher risk group, 26.3% compared to 46.7% and 44.6% in lower and intermediate risk groups respectively, p=0.052.

The model was externally validated in the Federazione Italiana Sindromi Mielodisplastiche (FISiM) database. The validation cohort lacked albumin value, but still predicted outcomes. Among 191 MDS-SF3B1 pts: 52, 106, 25, 7 and 1 pt respectively were VL, L, ML, MH, H or VH IPSS-M risk. By the new model 35% (66), 47% (90), and 18% (35) were low, intermediate, or high risk respectively. The median OS was NR, 69.5 mo, and 50.7 mo for the 3 risk groups, p < 0.005. The median LFS was NR, 67.8, and 50.7 mo respectively for the 3 risk groups, p < 0.005. The c index was 0.654 for OS and 0.649 for LFS.

Conclusions

Most patients with MDS-SF3B1 are classified as VL or L risk by IPSS-M, limiting the identification of individuals with poorer outcome. We developed a prognostic model that integrates clinical and genomic features to improve risk stratification and predict both overall survival and leukemia-free survival in MDS-SF3B1.

 

Rami Komrokji, MD: Abbvie - Honoraria; syndax - Honoraria; Takeda - Honoraria; Stemline - Honoraria; DSI - Honoraria; BMS - Honoraria; GSK - Honoraria; RIGEL - Honoraria; Sobi - Honoraria; Kura - Honoraria; Servier - Honoraria; Novartis - Honoraria; Sumitomo - Honoraria; GERON - Honoraria; PharmaEssentia - Honoraria; BMS - Research Funding; Takeda - Consultancy (Includes expert testimony); RIGEL - Consultancy (Includes expert testimony); syndax - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); DSI - Consultancy (Includes expert testimony); GERON - Consultancy (Includes expert testimony); Kura - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony)